Alexion Pharm Inc (ALXN) Stock Price, Forecast & Analysis
USA - NASDAQ:ALXN -
ALXN Key Statistics, Chart & Performance
The current stock price of ALXN is 182.5 null. In the past month the price increased by 1.02%. In the past year, price increased by 79.82%.
ALXN Latest News, Press Relases and Analysis
ALXN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.68 | 412.02B | ||
| AMGN | AMGEN INC | 15.39 | 181.16B | ||
| GILD | GILEAD SCIENCES INC | 15.08 | 153.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.85 | 110.59B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.25 | 72.76B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 892.49 | 59.66B | ||
| INSM | INSMED INC | N/A | 40.94B | ||
| NTRA | NATERA INC | N/A | 28.62B | ||
| BIIB | BIOGEN INC | 9.55 | 23.45B | ||
| INCY | INCYTE CORP | 16.9 | 21.18B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.41 | 20.78B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.81 | 14.43B |
Related stock screener links
About ALXN
Company Profile
Alexion Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 3,837 full-time employees. The firm is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS is an C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses prescribed.
Company Info
Alexion Pharm Inc
121 Seaport Blvd
Boston MASSACHUSETTS 02210 US
CEO: Ludwig N. Hantson
Employees: 3837
Phone: 14752302596.0
Alexion Pharm Inc / ALXN FAQ
Can you describe the business of Alexion Pharm Inc?
Alexion Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 3,837 full-time employees. The firm is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS is an C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses prescribed.
Can you provide the latest stock price for Alexion Pharm Inc?
The current stock price of ALXN is 182.5 null. The price increased by 1.7% in the last trading session.
Does ALXN stock pay dividends?
ALXN does not pay a dividend.
What is the ChartMill rating of Alexion Pharm Inc stock?
ALXN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Should I buy ALXN stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALXN.
What is the employee count for ALXN stock?
Alexion Pharm Inc (ALXN) currently has 3837 employees.
Can you provide the market cap for Alexion Pharm Inc?
Alexion Pharm Inc (ALXN) has a market capitalization of 40.34B null. This makes ALXN a Large Cap stock.
ALXN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ALXN. When comparing the yearly performance of all stocks, ALXN is one of the better performing stocks in the market, outperforming 83.7% of all stocks.
ALXN Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ALXN. Both the profitability and the financial health of ALXN get a neutral evaluation. Nothing too spectacular is happening here.
ALXN Financial Highlights
Over the last trailing twelve months ALXN reported a non-GAAP Earnings per Share(EPS) of 12.83. The EPS increased by 12.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.89% | ||
| ROA | 3.66% | ||
| ROE | 5.48% | ||
| Debt/Equity | 0.19 |
ALXN Forecast & Estimates
13 analysts have analysed ALXN and the average price target is 180.9 null. This implies a price decrease of -0.87% is expected in the next year compared to the current price of 182.5.
For the next year, analysts expect an EPS growth of 9.86% and a revenue growth 12.08% for ALXN